PreCision Dermatology Names Garen Bohlin to Board of Directors

NEW YORK--()--PreCision Dermatology, Inc., a leader in developing and commercializing novel, prescription and physician dispensed products for improving skin health, today announced today that it has appointed Garen Bohlin to its Board of Directors, effective immediately.

"We are delighted to welcome an executive with the broad-based health-care industry experience that Garen Bohlin brings to the PreCision board. The depth of his experience, including his strong financial background, will be extremely helpful as we address our future growth opportunities," said Jeffrey Nugent, President and Chief Executive Officer.

Mr. Bohlin has held senior executive posts in leading biotechnology companies for the past 27 years. Most recently, as the Executive Vice President of Constellation Pharmaceuticals, he also assumed the role of general business partner to the CEO where he was instrumental in consummating option-to-acquire and pre-negotiated merger agreements with Genentech. Prior to his role at Constellation, Mr. Bohlin was Chief Operating Officer of Sirtris Pharmaceuticals, where he played key roles in the overall management of Sirtris, its initial public offering and the sale of the company to GlaxoSmithKline for more than $700 million. Prior to his tenure at Sirtris, Mr. Bohlin was the founding Chief Executive Officer of Syntonix Pharmaceuticals where he positioned the company for its eventual sale to Biogen Idec. Mr. Bohlin began his career in the biotechnology sector at Genetics Institute, where he held multiple executive positions culminating with responsibility for most of the company’s non- scientific areas, and played an integral role in structuring the sale of Genetics Institute to American Home Products (Wyeth) at an implied valuation of approximately $3 billion. Mr. Bohlin was a partner at Arthur Andersen & Co. before assuming various operating roles in the life sciences field and currently serves on the Boards of Directors of Acusphere, Inc., Springleaf Therapeutics, Inc. and Tetraphase Pharmaceuticals, Inc.

About PreCision Dermatology, Inc.

Headquartered in New York and Cumberland, Rhode Island, PreCision Dermatology is a fully- integrated dermatology company with a mission to deliver innovative therapies to physicians and patients that demonstrably improve the skin. PreCision Dermatology is rapidly expanding through internally generated innovation, acquisitions, in-licensing, and co-marketing opportunities. For additional information, please visit www.precisionderm.com

Contacts

PreCision Dermatology, Inc.
Steven N. Tannenbaum, 401-762-2000 ext. 216
Executive VP & CFO
stannenbaum@precisionderm.com

Sharing

Contacts

PreCision Dermatology, Inc.
Steven N. Tannenbaum, 401-762-2000 ext. 216
Executive VP & CFO
stannenbaum@precisionderm.com